Resources

1 Resources for

a novo nordisk executive

  • Subscribe to this listing via:
  • RSS
  • Email

BNET Resources

Novo Nordisk Exec Charged With Insider Trading; Cash Stashed in Caribbean
A Novo Nordisk executive has been fired and is being held on remand for alleged insider trading in the company's stock, according to the Copenhagen Post. He garnered 6 million kroner by trading on Novo stock, stashing the riches in an offshore account in the Caribbean. by Jim Edwards
Tags: Stock, Insider, A Novo Nordisk Executive, Investment, Outsourcing, Finance, It Operations, Business Operations, Outsourcing & Subcontracting, Jim Edwards
Blog posts 2009-09-04

Additional Resources

Novo Nordisk Executive Compensation: A Picture of Modesty (Except for the Car Expenses)
Novo Nordisk's annual report is out and it contains some interesting stuff on senior management compensation. CEO Lars Rebien Sørensen received total compensation of DKK10.8 million (about $1.8 million). That was modest compared to his counterparts at American companies. (At Eli Lilly, CEO John Lechleiter got $13...
Tags: Car, Compensation, Novo Nordisk, Benefits, Human Resources, Jim Edwards
Blog posts 2009-02-17
NOVO NORDISK: EU approval of NovoNorm, Novo Nordisk's new oral treatment for Type 2 diabetes.
M2 PRESSWIRE-17 August 1998-NOVO NORDISK: EU approval of NovoNorm, Novo Nordisk's new oral treatment for Type 2 diabetes C1994-98 M2 COMMUNICATIONS LTD RDATE:170898 Novo Nordisk A/S (NYSE:NVO) today announced that the European Commission has approved NovoNorm (repaglinide - Prandin in the...
Tags: agent, European Commission
Research articles 1998-08-17
Novo Nordisk pays R$130mil for Biobras.
Brazil, Dec 5, 2002 (Gazeta Mercantil/SABI via COMTEX) ABN Amro is to announce the completion of the shares acquisition operation of the Brazilian pharmaceutical company Biobras on behalf of the Danish Novo Nordisk, in a move worth R$130mil, R$55.7mil of which paid to minority...
Tags: ABN AMRO, FINANCE, Investment
Research articles 2002-12-06
Gilead Executive Pay: Modest Raises for Outstanding Performance
Gilead CEO John C Martin got a negligible pay raise in 2008, despite the fact that his company largely met its performance goals. Revenue was up, net income was up, and the stock price held (it's still double the price it was in 2004). Yet Martin's total...
Tags: Benefits, CEO, CFO, Compensation, Gilead Sciences Inc., Human Resources, Jim Edwards, Performance, Pharmaceutical Company
Blog posts 2009-03-16
Valeant Executive Pay Doubles to $19.7 Million Despite Quadrupling of Company's Losses
Valeant Pharmaceuticals saw its revenues decline, its net loss quadruple, and its cash sink by $109 million in 2008. But the compensation of its top executives doubled, to $19.7 million in 2008 from $8.6 million in 2007. Half of that, $9.7 million, went to CEO J. Michael...
Tags: Compensation, Pharmaceutical Company, CEO, Benefits, Human Resources, Jim Edwards
Blog posts 2009-03-27
Abbott CEO White Takes a Pay Cut
Abbott Labs CEO Miles White took a pay cut last year. His total compensation was only $28.3 million, down from $33.3 million the year before, per a proxy filing at the SEC. The cut came despite the judgment by Abbott's board that White "exceeded" his strategic and...
Tags: Agreement, Exec, CEO, Abbott Labs, Performance Management, Human Resources, Workforce Management, Jim Edwards
Blog posts 2009-03-18
King Pharma Pay Rises 12.3%; CEO Markison Got $100,000 in Personal Jet Rides
Executive pay at King Pharmaceuticals rose 12.3 percent in 2008 even though the company's stock -- with which pay is supposed to be aligned -- stayed flat. Despite the drama of the AlPharma acquisition, King had a mixed year in 2008, on balance. Revenues were down 26...
Tags: Compensation, Exec, CEO, Stock Performance, Personal Flight, Benefits, Human Resources, Jim Edwards
Blog posts 2009-04-24
Allergan CEO Pyott Received Pay Raise to $11.9 Million
Allergan CEO David Pyott received a 6 percent raise in total compensation last year, bringing his pay packet to $11.9 million. The top five executives of Allergan all got pay raises. Their total combined compensation rose 10 percent to $24 million. Over the year, Allergan fared well....
Tags: Allergan Inc., CEO, Benefits, Human Resources, Jim Edwards
Blog posts 2009-03-23
Shire CEO Compensation Report Successfully Conceals CEO Compensation
Shire, the British company that markets Adderall and Vyvanse, has produced a compensation report for its senior executives that is all but impossible to understand. The disclosure, starting on page 52 of the annual report, describes the compensation of just three of its top executives -- former...
Tags: Compensation, Exec, CEO, Shire, Values, Benefits, Human Resources, Jim Edwards
Blog posts 2009-03-25
Wyeth CEO Got 69% Pay Raise; Was "Required" to Use Helicopter; Plus $24 Million Pfizer Sale Bonus
Wyeth CEO Bernard Poussot received a 69 percent compensation raise in 2008, to $21.3 million, in addition to a $24 million change-in-control bonus for selling his company to Pfizer.* Wyeth also took the explanation of executive perks to new levels, saying that Wyeth "requires" Poussot to travel...
Tags: Wyeth, Compensation, Pfizer Inc., Exec, CEO, Norden, Benefits, Taxes, Human Resources, Financial Planning, Finance, Jim Edwards
Blog posts 2009-03-30
Medicis Doubled Pay of Exec Convicted of Off-Label Sales
Medicis more than doubled the pay of its sales chief in 2008 even though that executive, Richard Havens, pled guilty to conspiracy to violate the Food and Drug Act last March. Havens, the former evp of sales, and three of his underlings pleaded guilty right before his April retirement to...
Tags: Compensation, Pharmaceutical Company, Allergan Inc., Exec, CEO, Sales Strategy, Benefits, Sales Force Management, Sales, Human Resources, Jim Edwards
Blog posts 2009-04-08
Medarex Execs Got 10% Pay Raise Despite Delivering Nothing
If there's a pharma company that rewards executives for delivering absolutely nothing, thy name is Medarex. Consider its record in 2008: Revenues declined from $56.2 million to $52.3 million. Its net loss expanded from $27 million to $38.5 million. The company has never made a...
Tags: Compensation, Exec, CEO, Benefits, Human Resources, Jim Edwards
Blog posts 2009-04-09
Rating and Ranking "Stealth Pharmas"
A "stealth pharma," according to the folks at Pharmaceutical Executive, is any drug company that's not a Big Pharma. In other words, it's grab-bag of outfits that includes everything from specialty pharmas hawking retread drugs to biotechs to generics makers. Which, of course, makes them difficult to...
Tags: Gilead Sciences Inc., Pharmaceutical Company, David P. Hamilton
Blog posts 2008-06-26
Need to know: Logitech acquisition ... Macy's loss ... Henkel profits up ...
View video and Need to Know interactive heatmap Economics Unemployment: Official figures showed that the unemployment rate rose by 30,000 to 2.46 million in the three months to the end of September, compared with the figures for the previous quarter. Economic growth: The Bank of England has surprised analysts by...
Tags: company, American International Group Inc., Guardian Media Group Plc.
News items 2009-11-11
Icahn Bruising For Proxy Battle With Amylin Management
[caption id="attachment_248" align="alignleft" width="200" caption="Byetta"][/caption] Activist investor Carl Icahn announced in a regulatory filing with the Securities and Exchange Commission his intention to nominate a slate of five directors to the board of Amylin Pharmaceuticals at the drugmaker’s May 2009 annual...
Tags: FDA, Patient, Byetta, Activist Investor Carl Icahn, Federal Government, Government, David Phillips
Blog posts 2009-01-29
  • << Previous
  • page 1 of 1
  • Next >>
advertisement
advertisement